Clinical trials
Recherche d’études cliniques
Recherchez uniquement dans les études cliniques enregistrées dans Biomedical Watch.
Études cliniques 612
| Étude / NCT ⇅ | Molécule ⇅ | Maladie ⇅ | Phase ⇅ | Statut ⇅ | Résultat ⇅ | Sponsor ⇅ | Pays / centres ⇅ | Période ⇅ | Détail |
|---|---|---|---|---|---|---|---|---|---|
| NCT07207148 People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agoni… |
GLP-1 | SEP | À vérifier | RECRUITING | En attente / non publié | Northwestern University | United States · Northwestern Memorial Hospital, Chica… | 2025-11-15 → 2028-08-31 | Ouvrir |
| NCT05974839 Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With … |
Effect of Ocrelizumab on Cortical… | SEP | À vérifier | COMPLETED | En attente / non publié | State University of New York at B… | United States · Buffalo Neuroimaging Analysis Center,… | 2023-10-01 → 2024-02-28 | Ouvrir |
| NCT05974852 ORATORIO-CP — Effect of Ocrelizumab on Choroid Plexus Changes in Patien… |
ORATORIO-CP — Effect of Ocrelizum… | SEP | À vérifier | COMPLETED | En attente / non publié | State University of New York at B… | United States · Buffalo Neuroimaging Analysis Center,… | 2023-10-01 → 2023-12-30 | Ouvrir |
| NCT04293458 ESOGUARDBE1 — Efficacy of EsoGuard on Samples Collected Using EsoCheck … |
EsoGuard | SEP | NA | COMPLETED | En attente / non publié | Lucid Diagnostics, Inc. | United States, Spain · Lucid Investigative Site, Chap… | 2020-02-28 → 2022-08-22 | Ouvrir |
| NCT04295811 ESOGUARDBE2 — Efficacy of EsoGuard Assay on Esophageal Surface Cells Co… |
EsoGuard (lab assay) | SEP | NA | UNKNOWN | En attente / non publié | Lucid Diagnostics, Inc. | United States, Netherlands · Lucid Investigative Site… | 2020-06-18 → 2023-12 | Ouvrir |
| NCT07609537 ICLDR-NAR Tria — Imagery Control Therapy and Lucid Dreaming for REM-Rel… |
ICLDR-NAR Tria — Imagery Control … | SEP | NA | COMPLETED | En attente / non publié | Institute of Behavioral Sleep Med… | Colombia · Bahavioral Sleep Medicine Institute, Medel… | 2024-03-01 → 2025-06-15 | Ouvrir |
| NCT01194570 ORATORIO — A Study of Ocrelizumab in Participants With Primary Progress… |
Ocrelizumab | SEP | Phase 3 | COMPLETED | En attente / non publié | Hoffmann-La Roche | United States, Australia, Austria, Belgium, Brazil, B… | 2011-03-02 → 2022-12-31 | Ouvrir |
| NCT02471560 TECONGUT — Tecfidera and the Gut Microbiota |
dimethyl fumarate | SEP | Phase 4 | COMPLETED | En attente / non publié | Biogen | Norway · Research site, Drammen, Norway | Research si… | 2015-11-06 → 2017-06-12 | Ouvrir |
| NCT05051618 METS in MS — Exercise Training for Managing Major Depressive Disorder i… |
METS in MS — Exercise Training fo… | SEP | NA | RECRUITING | En attente / non publié | University of Illinois at Chicago | United States · University of Illinois at Chicago, Ch… | 2023-04-01 → 2026-10-31 | Ouvrir |
| NCT01617395 Relating Genetic and Environmental Risk Scores to Multiple Sclerosis Su… |
Relating Genetic and Environmenta… | SEP | À vérifier | COMPLETED | En attente / non publié | National Institute of Neurologica… | United States · National Institutes of Health Clinica… | 2012-08-15 | Ouvrir |
| NCT04062331 Transcranial Magnetic Stimulation (TMS) in Multiple Sclerosis |
Transcranial Magnetic Stimulation… | SEP | Phase 1 | UNKNOWN | En attente / non publié | Neuromed IRCCS | Non communiqué | 2019-10-01 → 2022-10-01 | Ouvrir |
| NCT01714089 Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing R… |
RNS60 125 ml | SEP | Phase 2 | WITHDRAWN | En attente / non publié | Revalesio Corporation | United States · Mt. Sinai School of Medicine, New Yor… | Non communiqué | Ouvrir |
| NCT04410978 Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine … |
Tolebrutinib | SEP | Phase 3 | COMPLETED | En attente / non publié | Sanofi | United States, Austria, Belarus, Bulgaria, Canada, Ch… | 2020-06-30 → 2024-07-15 | Ouvrir |
| NCT06064539 Study of Drug-drug Interaction of the Effects of Gemfibrozil and Rifamp… |
Tolebrutinib | SEP | Phase 1 | COMPLETED | En attente / non publié | Sanofi | United States · Prism Research-Site Number:8400001, S… | 2020-05-18 → 2020-07-08 | Ouvrir |
| NCT07411924 Mastication, Cognition, and Nutritional Status in Multiple Sclerosis |
Mastication, Cognition, and Nutri… | SEP | À vérifier | NOT_YET_RECRUITING | En attente / non publié | Ondokuz Mayıs University | Non communiqué | 2026-03-01 → 2026-12-01 | Ouvrir |
| NCT03493841 Comparing Tolerability and Absorption of Racemic and R-lipoic Acid in P… |
Alpha Lipoic Acid | SEP | Phase 1 | COMPLETED | En attente / non publié | Rebecca Spain | United States · Oregon Health & Science University, P… | 2018-06-08 → 2019-01-25 | Ouvrir |
| NCT04285346 Adjunctive Ganaxolone Treatment (Part A) in TSC Followed by Long-term T… |
Ganaxolone | SEP | Phase 2 | COMPLETED | En attente / non publié | Marinus Pharmaceuticals | United States · Marinus Research Site, Boston, United… | 2020-04-08 → 2022-08-30 | Ouvrir |
| NCT02061397 Safety of Simvastatin in LAM and TSC |
Simvastatin | SEP | Phase 1 | COMPLETED | En attente / non publié | University of Pennsylvania | United States · University of Pennsylvania, Philadelp… | 2014-03 → 2019-12-13 | Ouvrir |
| NCT05422339 Efficacy of Gamification in Enhancing User Engagement |
The MapHabit system (MHS) | Alzheimer | NA | COMPLETED | En attente / non publié | MapHabit, Inc. | United States · MapHabit, Atlanta, United States | 2022-09-12 → 2023-12-28 | Ouvrir |
| NCT03574428 Single Ascending Doses Study With GNbAC1 in Healthy Male Volunteers |
GNbAC1 | SEP | Phase 1 | COMPLETED | En attente / non publié | GeNeuro Australia PTY Ltd | Australia · Scientia Clinical Research Ltd, Sydney, A… | 2018-05-08 → 2018-11-02 | Ouvrir |
| NCT02538094 tDCS and Cognition in Adults With Multiple Sclerosis or Encephalitis |
Sham Transcranial direct current … | SEP | NA | COMPLETED | En attente / non publié | The University of Texas at Dallas | United States · Johns Hopkins East Baltimore Campus; … | 2014-09 → 2019-06-30 | Ouvrir |
| NCT03798366 A Clinical Study to Test How Effective and Safe GLPG1690 is for Partici… |
GLPG1690 | SEP | Phase 2 | COMPLETED | En attente / non publié | Lakefront Biotherapeutics NV | United States, Belgium, Germany, Italy, Spain, United… | 2019-01-14 → 2020-06-22 | Ouvrir |
| NCT02601131 Post-transfusion Platelet Count |
Platelet transfusion | SEP | À vérifier | COMPLETED | En attente / non publié | Region Skane | Sweden · Region Skåne, Lund, Sweden | 2016-02 → 2016-09 | Ouvrir |
| NCT05357781 Immunoglobulin Deficiency a Treatable Cause of Fatigue in Patients With… |
Immunoglobulin Deficiency a Treat… | SEP | À vérifier | RECRUITING | En attente / non publié | Insel Gruppe AG, University Hospi… | Switzerland · University Hospital of Bern Inselspital… | 2022-07-01 → 2026-12-30 | Ouvrir |
| NCT02874677 A Reeducation Program to Effort to Improve the Walking of Multiple Scle… |
A Reeducation Program to Effort t… | SEP | NA | TERMINATED | En attente / non publié | Lille Catholic University | France · Centre Hospitalier Régional Universitaire de… | 2017-12-07 → 2022-01-14 | Ouvrir |